Journal of Food Science, Nutrition and Health Vol.3 EWA Publishing
Published Online: 30 September 2024 DOI: 10.54254/3029-0821/3/2024019

The role of TGF-β receptor mutations in epithelial-mesenchymal transition and metastasis in lung cancer

Bohan Huang

Oaks Christian High School, California, US

BHuang@student.oakschristian.org

Abstract. Lung cancer is one of the leading causes of cancer mortality around the world. The progression of lung cancer is often marked by the metastasis, which is a progress where the lung cancer cells start to spread out to other organs and systems in our human body. This progression is always marked by the scientists as the sign of the mortality of the patient. Epithelial-mesenchymal transition (EMT) is a critical process in the development of lung cancer, contributing to metastasis and resistance to therapy. EMT facilitates the invasion of the cancer cell, and prevents the apoptosis. EMT also enhances tumor cell survival, and resistance to the conventional chemotherapy or target treatment. It is an important process that leads to the spread of cancer cell and cause death. This essay focuses on the molecule transforming growth factor-beta (TGF-β), which plays a central role in regulating EMT. In particular, mutations in TGF-β receptors significantly impact this process. This essay examines the effects of TGF-β receptor mutations on EMT in lung cancer, analyzing common and emerging mutations, their functional consequences, and the potential therapeutic implications. By exploring the altered signaling pathways and their effects on EMT markers, this study provides insights into the role of TGF-β receptor mutations in lung cancer metastasis and prognosis.

Keywords: epithelial-mesenchymal transition, transforming growth factor-beta, signaling pathway, metastasis

1. Introduction

Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Metastasis is the primary reason for the spread of lung cancer throughout the body, contributing to increased mortality rates. Epithelial-mesenchymal transition (EMT) is a crucial mechanism in cancer progression, and transforming growth factor-beta (TGF-β) signaling is a key regulator of EMT. Mutations in TGF-β receptors may play a significant role in the regulation of metastasis. This essay aims to analyze the impact of TGF-β receptor mutations on EMT in lung cancer and to explore their potential as therapeutic targets.

2. Main part

2.1. Background on EMT in cancer

EMT is a complex and dynamic process that plays a critical role in cancer progression, particularly in the context of metastasis and resistance to therapy. During EMT, epithelial cells lose their polarity and adhesion properties, transitioning into a mesenchymal phenotype characterized by increased motility and invasiveness. This process is driven by various signaling pathways, with TGF-β signaling being one of the most significant contributors. In lung cancer, EMT is associated with poor prognosis due to its role in facilitating metastasis, making it a key target for therapeutic intervention. [1]

2.2. Significance of TGF-β signaling in EMT

TGF-β signaling is a highly conserved pathway that regulates a wide range of cellular processes, including proliferation, differentiation, and apoptosis. In cancer, TGF-β signaling is known to play a dual role, acting as a tumor suppressor in early stages and as a promoter of tumor progression and metastasis in later stages. [2] The pathway is initiated when TGF-β ligands bind to TGF-β receptors, leading to the activation of downstream signaling cascades. Mutations in TGF-β receptors can significantly alter the signaling efficacy, thereby impacting the regulation of EMT and influencing cancer progression. [3]

2.3. Objective

The primary objective of this essay is to analyze the impact of TGF-β receptor mutations on EMT in lung cancer. This analysis includes an exploration of common and emerging mutations, their functional consequences on TGF-β signaling, and the potential implications for lung cancer metastasis and therapy.

2.4. Common mutations in lung cancer

Mutations in TGF-β receptors, particularly TGFBR1 and TGFBR2, are frequently observed in various cancers, including lung cancer. These mutations can lead to either loss-of-function or gain-of-function, each with distinct effects on TGF-β signaling and EMT. Databases such as the Catalogue of Somatic Mutations in Cancer (COSMIC) and The Cancer Genome Atlas (TCGA) have been instrumental in identifying prevalent TGF-β receptor mutations in lung cancer. [4] These databases provide a comprehensive overview of the mutational landscape, highlighting mutations that may contribute to cancer progression through altered TGF-β signaling.

2.5. Mutation detection techniques

The identification of TGF-β receptor mutations is achieved through various molecular techniques, including next-generation sequencing (NGS), polymerase chain reaction (PCR), and Sanger sequencing. NGS, in particular, has revolutionized the detection of genetic alterations, allowing for high-throughput and comprehensive analysis of cancer genomes. [5] PCR and Sanger sequencing remain valuable tools for validating NGS findings and detecting specific mutations in targeted regions of TGF-β receptors.

3. Emerging mutations and variants

3.1. Rare and novel mutations

In addition to common mutations, emerging rare and novel mutations in TGF-β receptors have been identified, which may have significant implications for lung cancer progression. These mutations are often not well-documented in existing databases but can be critical in modulating TGF-β signaling and EMT. [6] Continued research into these emerging mutations is essential for understanding their potential impact on cancer therapy and patient outcomes.

3.2. Impact of genetic variants

Genetic variants, such as single nucleotide polymorphisms (SNPs), in TGF-β receptors can also modulate EMT by affecting the receptor's function and signaling efficacy. These variants may contribute to interpatient variability in response to therapy and prognosis, making them important factors to consider in the development of personalized treatment strategies. [7]

3.3. Functional impact of TGF-β receptor mutations

Loss-of-function mutations in TGF-β receptors can lead to impaired signaling, resulting in a reduced ability to induce EMT. This impairment may decrease the metastatic potential of lung cancer cells, as EMT is a key driver of metastasis. However, the loss of TGF-β signaling may also lead to resistance to therapies that rely on the induction of EMT, highlighting the complex role of these mutations in cancer progression. [8]

In contrast, gain-of-function mutations result in hyperactive TGF-β signaling, which can enhance EMT and promote metastasis. These mutations are often associated with poor prognosis in lung cancer, as they facilitate the transition of epithelial cells to a more aggressive mesenchymal phenotype. The identification of gain-of-function mutations in TGF-β receptors could provide valuable insights into the development of targeted therapies aimed at inhibiting excessive TGF-β signaling. [9]

4. Context-dependent effects

4.1. Tumor microenvironment

The effects of TGF-β receptor mutations on EMT are not solely determined by the mutations themselves but are also influenced by the tumor microenvironment. Factors such as hypoxia, extracellular matrix composition, and interactions with other cell types can modulate the impact of TGF-β signaling on EMT. Understanding the interplay between TGF-β receptor mutations and the tumor microenvironment is crucial for developing effective therapeutic strategies. [10]

4.2. Interaction with other signaling pathways

TGF-β signaling does not operate in isolation but interacts with other signaling pathways, such as PI3K/AKT and Wnt, that also regulate EMT. Crosstalk between these pathways can either amplify or attenuate the effects of TGF-β receptor mutations, leading to context-dependent outcomes in lung cancer progression. Investigating these interactions is essential for a comprehensive understanding of how TGF-β receptor mutations influence EMT. [11]

4.3. Impact on TGF-β signaling efficacy

Mutations in TGF-β receptors can alter ligand binding and receptor activation, leading to changes in downstream signaling pathways. These alterations can affect both SMAD-dependent and SMAD-independent pathways, which are critical for the regulation of EMT. By investigating how specific mutations impact these pathways, researchers can gain insights into the molecular mechanisms underlying EMT in lung cancer. [12]

4.4. Correlation with EMT markers

The expression levels of EMT markers, such as epithelial markers (E-cadherin) and mesenchymal markers (N-cadherin, vimentin), can provide valuable information on the impact of TGF-β receptor mutations on EMT. Analyzing these markers in lung cancer cells with TGF-β receptor mutations can help elucidate the functional consequences of these mutations and their role in cancer progression. [13]

5. Conclusion

TGF-β receptor mutations play a critical role in modulating EMT in lung cancer, with significant implications for metastasis and treatment strategies. Both loss-of-function and gain-of-function mutations can alter TGF-β signaling, leading to either reduced or enhanced EMT. The effects of these mutations are influenced by the tumor microenvironment and interactions with other signaling pathways, emphasizing the complexity of TGF-β signaling in cancer. Understanding the functional impact of TGF-β receptor mutations on EMT is essential for developing targeted therapies that can effectively manage lung cancer progression and improve patient outcomes.

References

[1] Nieto, M. A., Huang, R. Y. J., Jackson, R. A., & Thiery, J. P. (2016). EMT: 2016. *Cell*, 166(1), 21-45.
[2] Massagué, J. (2008). TGFβ in Cancer. *Cell*, 134(2), 215-230.
[3] Ikushima, H., & Miyazono, K. (2010). TGF-β signaling: a complex web in cancer progression. *Nature Reviews Cancer*, 10(6), 415-424.
[4] Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., ... & Campbell, P. J. (2017). COSMIC: somatic cancer genetics at high-resolution. *Nucleic Acids Research*, 45(D1), D777-D783.
[5] Mardis, E. R. (2008). Next-generation DNA sequencing methods. *Annual Review of Genomics and Human Genetics*, 9, 387-402.
[6] Pardali, K., & Moustakas, A. (2007). Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochimica et Biophysica Acta (BBA)-*Reviews on Cancer*, 1775(1), 21-62.
[7] Wells, J. D., Woon, T. P., Farooqi, A. A., & Hashmi, S. N. (2013). Genetic variants of TGF-β and cancer: How much do they contribute? *Journal of Cellular Biochemistry*, 114(3), 509-513.
[8] Levy, L., & Hill, C. S. (2005). Alterations in components of the TGF-β superfamily signaling pathways in human cancer. *Cytokine & Growth Factor Reviews*, 16(1), 61-80.
[9] Derynck, R., & Akhurst, R. J. (2007). TGF-β signaling in cancer—a double-edged sword. *Trends in Cell Biology*, 17(6), 286-295.
[10] Kalluri, R. (2016). The biology and function of fibroblasts in cancer. *Nature Reviews Cancer*, 16(9), 582-598.
[11] Gonzalez, D. M., & Medici, D. (2014). Signaling mechanisms of the epithelial-mesenchymal transition. *Science Signaling*, 7(344), re8.
[12] Massagué, J. (2012). TGFβ signalling in context. *Nature Reviews Molecular Cell Biology*, 13(10), 616-630.
[13] Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. *Cell*, 139(5), 871-890.